It’s not your imagination:
is issuing fewer enforcement letters to companies over drug promotions in 2016
than in previous years.
There “are not a lot of
enforcement letters so far this year,” Thomas Abrams, director
of the Food and Drug Administration's Office of Prescription Drug Promotion
a Food and Drug Law Institute conference in Washington.
But the decrease in letters doesn’t mean companies can afford to stop monitoring their drug marketing campaigns.
Indeed, Abrams stressed that the decrease in
s of letters being issued doesn't mean
a lower level of enforcement on the agency's part.
Warning and untitled letters are “just one
component of our multi
faceted approach to achieve the
objective of having nonmisleading, truthful and
balanced promotion,” Abrams said. Other facets include developing guidance
documents, reviewing draft product labeling and reviewing core launch
“We will work on issuing guidances on promotional issues,” he said, with the goal of achieving voluntary compliance.
As of Oct. 3, the OPDP had issued only four
enforcement letters in 2016 for drug marketing violations (14 PLIR 1314, 9/23/16). Three of those were untitled letters and
one was a warning letter. In 2015, OPDP issued
The OPDP issues warning letters and untitled letters to companies for drug marketing that doesn't meet the truthful, balanced and not-misleading promotional standard. An untitled letter cites violations that don't meet the threshold of regulatory significance for a warning letter, according to the agency's regulatory procedures manual. Such letters often are used for drug promotion violations.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)